Grifols S.A (G0FB) - Total Assets
Based on the latest financial reports, Grifols S.A (G0FB) holds total assets worth €19.77 Billion EUR (≈ $23.11 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See G0FB net asset value for net asset value and shareholders' equity analysis.
Grifols S.A - Total Assets Trend (2016–2024)
This chart illustrates how Grifols S.A's total assets have evolved over time, based on quarterly financial data.
Grifols S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Grifols S.A's total assets of €19.77 Billion consist of 26.8% current assets and 73.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.6% |
| Accounts Receivable | €705.45 Million | 3.3% |
| Inventory | €3.56 Billion | 16.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.93 Billion | 13.7% |
| Goodwill | €7.40 Billion | 34.6% |
Asset Composition Trend (2016–2024)
This chart illustrates how Grifols S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see G0FB market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Grifols S.A's current assets represent 26.8% of total assets in 2024, a decrease from 30.8% in 2016.
- Cash Position: Cash and equivalents constituted 4.6% of total assets in 2024, down from 8.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 46.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 34.6% of total assets.
Grifols S.A Competitors by Total Assets
Key competitors of Grifols S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX114.07 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
Grifols S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.64 | 1.68 | 2.86 |
| Quick Ratio | 0.95 | 0.80 | 1.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €3.26 Billion | €2.80 Billion | €2.31 Billion |
Grifols S.A - Advanced Valuation Insights
This section examines the relationship between Grifols S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.01 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 2.0% |
| Total Assets | €21.41 Billion |
| Market Capitalization | $1.99 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Grifols S.A's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Grifols S.A's assets grew by 2.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Grifols S.A (2016–2024)
The table below shows the annual total assets of Grifols S.A from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €21.41 Billion ≈ $25.02 Billion |
+1.97% |
| 2023-12-31 | €20.99 Billion ≈ $24.54 Billion |
-2.52% |
| 2022-12-31 | €21.53 Billion ≈ $25.18 Billion |
+11.96% |
| 2021-12-31 | €19.23 Billion ≈ $22.49 Billion |
+25.92% |
| 2020-12-31 | €15.27 Billion ≈ $17.86 Billion |
-1.72% |
| 2019-12-31 | €15.54 Billion ≈ $18.17 Billion |
+24.57% |
| 2018-12-31 | €12.48 Billion ≈ $14.59 Billion |
+14.26% |
| 2017-12-31 | €10.92 Billion ≈ $12.77 Billion |
+7.80% |
| 2016-12-31 | €10.13 Billion ≈ $11.84 Billion |
-- |
About Grifols S.A
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more